PDF(Pubmed)
Abstract：
BACKGROUND: The blood-brain barrier (BBB) regulates brain substance entry, posing challenges for treating brain diseases. Traditional methods face limitations, leading to the exploration of non-invasive intranasal drug delivery. This approach exploits the direct nose-to-brain connection, overcoming BBB restrictions. Intranasal delivery enhances drug bioavailability, reduces dosage, and minimizes systemic side effects. Notably, lipid nanoparticles, such as solid lipid nanoparticles and nanostructured lipid carriers, offer advantages like improved stability and controlled release. Their nanoscale size facilitates efficient drug loading, enhancing solubility and bioavailability. Tailored lipid compositions enable optimal drug release, which is crucial for chronic brain diseases. This review assesses lipid nanoparticles in treating neuro-oncological and neurodegenerative conditions, providing insights for effective nose-to-brain drug delivery.
METHODS: A systematic search was conducted across major medical databases (PubMed, Ovid MEDLINE, and Scopus) up to 6 January 2024. The search strategy utilized relevant Medical Subject Heading (MeSH) terms and keywords related to \"lipid nanoparticles\", \"intranasal administration\", \"neuro-oncological diseases\", and \"neurodegenerative disorders\". This review consists of studies in vitro, in vivo, or ex vivo on the intranasal administration of lipid-based nanocarriers for the treatment of brain diseases.
RESULTS: Out of the initial 891 papers identified, 26 articles met the eligibility criteria after a rigorous analysis. The exclusion of 360 articles was due to reasons such as irrelevance, non-reporting selected outcomes, the article being a systematic literature review or meta-analysis, and lack of method/results details. This systematic literature review, focusing on nose-to-brain drug delivery via lipid-based nanocarriers for neuro-oncological, neurodegenerative, and other brain diseases, encompassed 60 studies. A temporal distribution analysis indicated a peak in research interest between 2018 and 2020 (28.3%), with a steady increase over time. Regarding drug categories, Alzheimer\'s disease was prominent (26.7%), followed by antiblastic drugs (25.0%). Among the 65 drugs investigated, Rivastigmine, Doxorubicin, and Carmustine were the most studied (5.0%), showcasing a diverse approach to neurological disorders. Notably, solid lipid nanoparticles (SLNs) were predominant (65.0%), followed by nanostructured lipid carriers (NLCs) (28.3%), highlighting their efficacy in intranasal drug delivery. Various lipids were employed, with glyceryl monostearate being prominent (20.0%), indicating preferences in formulation. Performance assessment assays were balanced, with in vivo studies taking precedence (43.3%), emphasizing the translation of findings to complex biological systems for potential clinical applications.
CONCLUSIONS: This systematic review reveals the transformative potential of intranasal lipid nanoparticles in treating brain diseases, overcoming the BBB. Positive outcomes highlight the effectiveness of SLNs and NLCs, which are promising new approaches for ailments from AD to stroke and gliomas. While celebrating progress, addressing challenges like nanoparticle toxicity is also crucial.
METHODS: A systematic search was conducted across major medical databases (PubMed, Ovid MEDLINE, and Scopus) up to 6 January 2024. The search strategy utilized relevant Medical Subject Heading (MeSH) terms and keywords related to \"lipid nanoparticles\", \"intranasal administration\", \"neuro-oncological diseases\", and \"neurodegenerative disorders\". This review consists of studies in vitro, in vivo, or ex vivo on the intranasal administration of lipid-based nanocarriers for the treatment of brain diseases.
RESULTS: Out of the initial 891 papers identified, 26 articles met the eligibility criteria after a rigorous analysis. The exclusion of 360 articles was due to reasons such as irrelevance, non-reporting selected outcomes, the article being a systematic literature review or meta-analysis, and lack of method/results details. This systematic literature review, focusing on nose-to-brain drug delivery via lipid-based nanocarriers for neuro-oncological, neurodegenerative, and other brain diseases, encompassed 60 studies. A temporal distribution analysis indicated a peak in research interest between 2018 and 2020 (28.3%), with a steady increase over time. Regarding drug categories, Alzheimer\'s disease was prominent (26.7%), followed by antiblastic drugs (25.0%). Among the 65 drugs investigated, Rivastigmine, Doxorubicin, and Carmustine were the most studied (5.0%), showcasing a diverse approach to neurological disorders. Notably, solid lipid nanoparticles (SLNs) were predominant (65.0%), followed by nanostructured lipid carriers (NLCs) (28.3%), highlighting their efficacy in intranasal drug delivery. Various lipids were employed, with glyceryl monostearate being prominent (20.0%), indicating preferences in formulation. Performance assessment assays were balanced, with in vivo studies taking precedence (43.3%), emphasizing the translation of findings to complex biological systems for potential clinical applications.
CONCLUSIONS: This systematic review reveals the transformative potential of intranasal lipid nanoparticles in treating brain diseases, overcoming the BBB. Positive outcomes highlight the effectiveness of SLNs and NLCs, which are promising new approaches for ailments from AD to stroke and gliomas. While celebrating progress, addressing challenges like nanoparticle toxicity is also crucial.
摘要：
背景：血脑屏障（BBB）调节大脑物质进入，对治疗脑部疾病构成挑战。传统方法面临局限性，导致非侵入性鼻内给药的探索。这种方法利用了鼻子到大脑的直接连接，克服BBB限制。鼻内给药增强了药物的生物利用度，减少剂量，并最大限度地减少全身副作用。值得注意的是,脂质纳米粒，如固体脂质纳米粒和纳米结构脂质载体，提供改善的稳定性和控制释放等优点。它们的纳米级尺寸有助于有效的药物装载，提高溶解度和生物利用度。量身定制的脂质组合物能够实现最佳药物释放，这对慢性脑部疾病至关重要。这篇综述评估了脂质纳米颗粒在治疗神经肿瘤和神经退行性疾病中的作用，为有效的鼻-脑药物输送提供见解。
方法：在主要医学数据库中进行了系统搜索(PubMed，OvidMEDLINE,和Scopus）至2024年1月6日。搜索策略利用了与“脂质纳米颗粒”相关的相关医学主题标题(MeSH)术语和关键词，“鼻内给药”，“神经肿瘤疾病”，和“神经退行性疾病”。这篇综述包括体外研究，在体内，或离体鼻内施用用于治疗脑疾病的基于脂质的纳米载体。
结果：在最初的891篇论文中，经过严格分析，有26篇文章符合资格标准。排除360篇文章是由于不相关等原因，未报告的选定结果，本文是系统的文献综述或荟萃分析，缺乏方法/结果细节。这篇系统的文献综述，专注于通过基于脂质的纳米载体用于神经肿瘤学的鼻-脑药物递送，神经退行性疾病，和其他脑部疾病，包括60项研究。时间分布分析表明，2018年至2020年的研究兴趣达到顶峰（28.3%），随着时间的推移稳步增长。关于药物类别，阿尔茨海默病突出（26.7%），其次是抗肿瘤药物(25.0%)。在调查的65种药物中，Rivastigmine,阿霉素,卡莫司汀是研究最多的(5.0%)，展示了神经系统疾病的多样化方法。值得注意的是,固体脂质纳米粒(SLN)占主导地位(65.0%)，其次是纳米结构脂质载体（NLCs）（28.3%），突出了它们在鼻内给药中的功效。使用了各种脂质，单硬脂酸甘油酯突出(20.0%)，表明配方中的偏好。性能评估试验是平衡的，体内研究优先(43.3%)，强调将研究结果转化为复杂的生物系统，以实现潜在的临床应用。
结论：本系统综述揭示了鼻内脂质纳米粒治疗脑疾病的转化潜力，克服BBB积极成果突出了SLN和NLC的有效性，这是从AD到中风和神经胶质瘤的疾病的有希望的新方法。在庆祝进步的同时，解决纳米粒子毒性等挑战也至关重要。
方法：在主要医学数据库中进行了系统搜索(PubMed，OvidMEDLINE,和Scopus）至2024年1月6日。搜索策略利用了与“脂质纳米颗粒”相关的相关医学主题标题(MeSH)术语和关键词，“鼻内给药”，“神经肿瘤疾病”，和“神经退行性疾病”。这篇综述包括体外研究，在体内，或离体鼻内施用用于治疗脑疾病的基于脂质的纳米载体。
结果：在最初的891篇论文中，经过严格分析，有26篇文章符合资格标准。排除360篇文章是由于不相关等原因，未报告的选定结果，本文是系统的文献综述或荟萃分析，缺乏方法/结果细节。这篇系统的文献综述，专注于通过基于脂质的纳米载体用于神经肿瘤学的鼻-脑药物递送，神经退行性疾病，和其他脑部疾病，包括60项研究。时间分布分析表明，2018年至2020年的研究兴趣达到顶峰（28.3%），随着时间的推移稳步增长。关于药物类别，阿尔茨海默病突出（26.7%），其次是抗肿瘤药物(25.0%)。在调查的65种药物中，Rivastigmine,阿霉素,卡莫司汀是研究最多的(5.0%)，展示了神经系统疾病的多样化方法。值得注意的是,固体脂质纳米粒(SLN)占主导地位(65.0%)，其次是纳米结构脂质载体（NLCs）（28.3%），突出了它们在鼻内给药中的功效。使用了各种脂质，单硬脂酸甘油酯突出(20.0%)，表明配方中的偏好。性能评估试验是平衡的，体内研究优先(43.3%)，强调将研究结果转化为复杂的生物系统，以实现潜在的临床应用。
结论：本系统综述揭示了鼻内脂质纳米粒治疗脑疾病的转化潜力，克服BBB积极成果突出了SLN和NLC的有效性，这是从AD到中风和神经胶质瘤的疾病的有希望的新方法。在庆祝进步的同时，解决纳米粒子毒性等挑战也至关重要。
